Community-acquired pneumonia related to intracellular pathogens

Intensive Care Medicine

Volumn 42, Issue 9, 2016, Pages 1374-1386

  Cillóniz, Catia ^a   Torres, Antoni ^a   Niederman, Michael ^b   van der Eerden, Menno ^c   Chalmers, James ^d,e   Welte, Tobias ^f   Blasi, Francesco ^g  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Community acquired pneumonia; Etiology; Intracellular pathogens; Pneumonia

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CORTICOSTEROID; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ANTIGEN DETECTION; BACTERIUM CULTURE; CHLAMYDIA PNEUMONIAE; CHLAMYDIA PSITTACI; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; COXIELLA BURNETII; EPIDEMIOLOGY; HUMAN; INTRACELLULAR BACTERIUM; LEGIONELLA PNEUMOPHILA; MIXED INFECTION; MOLECULAR DIAGNOSIS; MYCOPLASMA PNEUMONIAE; NONHUMAN; PATHOGENESIS; REVIEW; SEROLOGY; COMMUNITY-ACQUIRED INFECTIONS; EUROPE; GRAM NEGATIVE INFECTION; MICROBIOLOGY; PNEUMONIA, BACTERIAL;

ANTI-BACTERIAL AGENTS; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY-ACQUIRED INFECTIONS; COXIELLA BURNETII; EUROPE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LEGIONELLA PNEUMOPHILA; MYCOPLASMA PNEUMONIAE; PNEUMONIA, BACTERIAL;

EID: 84976430876     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-016-4394-4     Document Type: Review

References (104)

1. File TM Jr, Marrie TJ (2010) Burden of community-acquired pneumonia in North American adults. Postgrad Med 122(2):130–141
2. Niederman MS (2007) Recent advances in community-acquired pneumonia: inpatient and outpatient. Chest 131(4):1205–1215
3. Ewig S, Woodhead M, Torres A (2011) Towards a sensible comprehension of severe community-acquired pneumonia. Intensive Care Med 37(2):214–223
4. Blasi F (2004) Atypical pathogens and respiratory tract infections. Eur Respir J 24(1):171–181
5. Cilloniz C, Ewig S, Polverino E et al (2012) Community-acquired pneumonia in outpatients: aetiology and outcomes. Eur Respir J 40(4):931–938
6. Dumke R, Schnee C, Pletz MW et al (2015) Mycoplasma pneumoniae and Chlamydia spp. infection in community-acquired pneumonia, Germany, 2011–2012. Emerg Infect Dis 21(3):426–434
7. Marrie TJ, Costain N, La SB et al (2012) The role of atypical pathogens in community-acquired pneumonia. Semin Respir Crit Care Med 33(3):244–256
8. Basarab M, Macrae MB, Curtis CM (2014) Atypical pneumonia. Curr Opin Pulm Med 20(3):247–251
9. Brown RJ, Farlane-Smith L, Phillips S, Chalker VJ (2015) Detection of macrolide resistant Mycoplasma pneumoniae in England, September 2014 to September 2015. Euro Surveill 20(48):30078
10. Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB (2009) Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr Infect Dis J 28(8):693–696
11. Jain S, Self WH, Wunderink RG et al (2015) Community-acquired pneumonia requiring Hospitalization among US adults. N Engl J Med 373(5):415–427
12. Cilloniz C, Ewig S, Polverino E et al (2011) Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 66(4):340–346
13. Capelastegui A, Espana PP, Bilbao A et al (2012) Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. BMC Infect Dis 12:134
14. Liu KT, Yang KY, Lee YC, Perng RP (2007) Risk factor analysis of acute respiratory distress syndrome among hospitalized patients with Chlamydophila pneumoniae pneumonia. J Chin Med Assoc 70(8):318–323
15. Viasus D, Di YS, Garcia-Vidal C et al (2013) Community-acquired Legionella pneumophila pneumonia: a single-center experience with 214 hospitalized sporadic cases over 15 years. Medicine (Baltimore) 92(1):51–60
16. Arnold FW, Summersgill JT, Lajoie AS et al (2007) A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 175(10):1086–1093
17. Cameron RL, Pollock KG, Lindsay DS, Anderson E (2015) Comparison of Legionella longbeachae and Legionella pneumophila cases in Scotland; implications for diagnosis, treatment and public health response. J Med Microbiol 65(2):142–146
18. Yu VL, Plouffe JF, Pastoris MC et al (2002) Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. J Infect Dis 186(1):127–128
19. Whiley H, Bentham R (2011) Legionella longbeachae and legionellosis. Emerg Infect Dis 17(4):579–583
20. Carratala J, Garcia-Vidal C (2010) An update on Legionella. Curr Opin Infect Dis 23(2):152–157
21. European Centre for Disease Prevention and Control (2016) Legionnaires’ disease surveillance in Europe, 2014. ECDC, Stockholm
22. Woodhead M (2002) Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J Suppl 36:20s–27s
23. Marston BJ, Plouffe JF, File TM Jr et al (1997) Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 157(15):1709–1718
24. Welte T, Torres A, Nathwani D (2012) Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67(1):71–79
25. Den Boer JW, Nijhof J, Friesema I (2006) Risk factors for sporadic community-acquired Legionnaires’ disease. A 3-year national case-control study. Public Health 120(6):566–571
26. Lanternier F, Tubach F, Ravaud P et al (2013) Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study. Chest 144(3):990–998
27. Farnham A, Alleyne L, Cimini D, Balter S (2014) Legionnaires’ disease incidence and risk factors, New York, New York, USA, 2002–2011. Emerg Infect Dis 20(11):1795–1802
28. Jacobson KL, Miceli MH, Tarrand JJ, Kontoyiannis DP (2008) Legionella pneumonia in cancer patients. Medicine (Baltimore) 87(3):152–159
29. Pletz MW, Rohde G, Schutte H, Bals R, von Baum H, Welte T, CAPNETZ-Studiengruppe (2011) Epidemiology and aetiology of community-acquired pneumonia (CAP). Dtsch Med Wochenschr 136(15):775–780
30. Lim WS, Baudouin SV, George RC et al (2009) BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 64(Suppl 3):iii1–55
31. Cilloniz C, Polverino E, Ewig S et al (2013) Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest 144(3):999–1007
32. Niederman MS, Mandell LA, Anzueto A et al (2001) Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730–1754
33. Miyashita N, Obase Y, Ouchi K et al (2007) Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit. J Med Microbiol 56(Pt 12):1625–1629
34. Izumikawa K, Izumikawa K, Takazono T et al (2014) Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia: a review of the Japanese literature. J Infect Chemother 20(3):181–185
35. Ewig S, Torres A (2003) Is Chlamydia pneumoniae an important pathogen in patients with community-acquired pneumonia? Eur Respir J 21(5):741–742
36. Chalmers JD, Rother C, Salih W, Ewig S (2014) Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 58(3):330–339
37. Lui G, Ip M, Lee N et al (2009) Role of ‘atypical pathogens’ among adult hospitalized patients with community-acquired pneumonia. Respirology 14(8):1098–1105
38. Phares CR, Wangroongsarb P, Chantra S et al (2007) Epidemiology of severe pneumonia caused by Legionella longbeachae, Mycoplasma pneumoniae, and Chlamydia pneumoniae: 1-year, population-based surveillance for severe pneumonia in Thailand. Clin Infect Dis 45(12):e147–e155
39. Petrovay F, Balla E (2008) Two fatal cases of psittacosis caused by Chlamydophila psittaci. J Med Microbiol 57(Pt 10):1296–1298
40. Fischer N, Rohde H, Indenbirken D et al (2014) Rapid metagenomic diagnostics for suspected outbreak of severe pneumonia. Emerg Infect Dis 20(6):1072–1075
41. Haas LE, Tjan DH, Schouten MA, van Zanten AR (2006) Severe pneumonia from psittacosis in a bird-keeper. Ned Tijdschr Geneeskd 150(3):117–121
42. Gacouin A, Revest M, Letheulle J et al (2012) Distinctive features between community-acquired pneumonia (CAP) due to Chlamydophila psittaci and CAP due to Legionella pneumophila admitted to the intensive care unit (ICU). Eur J Clin Microbiol Infect Dis 31(10):2713–2718
43. Knittler MR, Sachse K (2015) Chlamydia psittaci: update on an underestimated zoonotic agent. Pathog Dis 73(1):1–15
44. Marrie TJ, Raoult D (1997) Q fever–a review and issues for the next century. Int J Antimicrob Agents 8(3):145–161
45. Pebody RG, Wall PG, Ryan MJ, Fairley C (1996) Epidemiological features of Coxiella burnetii infection in England and Wales: 1984 to 1994. Commun Dis Rep CDR Rev 6(9):R128–R132
46. Roest HI, Ruuls RC, Tilburg JJ et al (2011) Molecular epidemiology of Coxiella burnetii from ruminants in Q fever outbreak, the Netherlands. Emerg Infect Dis 17(4):668–675
47. Dijkstra F, van der Hoek W, Wijers N et al (2012) The 2007–2010 Q fever epidemic in the Netherlands: characteristics of notified acute Q fever patients and the association with dairy goat farming. FEMS Immunol Med Microbiol 64(1):3–12
48. Dahlgren FS, Haberling DL, McQuiston JH (2015) Q fever is underestimated in the United States: a comparison of fatal Q fever cases from two national reporting systems. Am J Trop Med Hyg 92(2):244–246
49. Schack M, Sachse S, Rodel J et al (2014) Coxiella burnetii (Q fever) as a cause of community-acquired pneumonia during the warm season in Germany. Epidemiol Infect 142(9):1905–1910
50. Schimmer B, Ter SR, Wegdam M et al (2010) The use of a geographic information system to identify a dairy goat farm as the most likely source of an urban Q-fever outbreak. BMC Infect Dis 10:69
51. Wielders CC, Wuister AM, de Visser V et al (2014) Characteristics of hospitalized acute Q fever patients during a large epidemic, the Netherlands. PLoS One 9(3):e91764
52. Hartzell JD, Wood-Morris RN, Martinez LJ, Trotta RF (2008) Q fever: epidemiology, diagnosis, and treatment. Mayo Clin Proc 83(5):574–579
53. Cilloniz C, Ewig S, Ferrer M et al (2011) Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Crit Care 15(5):R209
54. Correia AM, Ferreira JS, Borges V et al (2016) Probable person-to-person transmission of Legionnaires’ disease. N Engl J Med 374(5):497–498
55. Nilsson AC, Bjorkman P, Welinder-Olsson C, Widell A, Persson K (2010) Clinical severity of Mycoplasma pneumoniae (MP) infection is associated with bacterial load in oropharyngeal secretions but not with MP genotype. BMC Infect Dis 10:39
56. Jiang W, Qian L, Liang H, Tian M, Liu F, Zhao D (2014) Relationships between the varied ciliated respiratory epithelium abnormalities and severity of Mycoplasma pneumoniae pneumonia. Scand J Infect Dis 46(7):486–492
57. Kannan TR, Provenzano D, Wright JR, Baseman JB (2005) Identification and characterization of human surfactant protein A binding protein of Mycoplasma pneumoniae. Infect Immun 73(5):2828–2834
58. Hanada S, Morozumi M, Takahashi Y et al (2014) Community-acquired pneumonia caused by macrolide-resistant Mycoplasma pneumoniae in adults. Intern Med 53(15):1675–1678
59. Miyashita N, Maruyama T, Kobayashi T et al (2011) Community-acquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients more than 18 years of age. J Infect Chemother 17(1):114–118
60. Cao B, Zhao CJ, Yin YD et al (2010) High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis 51(2):189–194
61. Waites KB, Talkington DF (2004) Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 17(4):697–728
62. Narita M (2010) Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia. J Infect Chemother 16(3):162–169
63. Tanaka H, Narita M, Teramoto S et al (2002) Role of interleukin-18 and T-helper type 1 cytokines in the development of Mycoplasma pneumoniae pneumonia in adults. Chest 121(5):1493–1497
64. Marrie TJ, Peeling RW, Reid T, De CE (2003) Chlamydia species as a cause of community-acquired pneumonia in Canada. Eur Respir J 21(5):779–784
65. Kern JM, Maass V, Maass M (2009) Molecular pathogenesis of chronic Chlamydia pneumoniae infection: a brief overview. Clin Microbiol Infect 15(1):36–41
66. Dupuis G, Petite J, Peter O, Vouilloz M (1987) An important outbreak of human Q fever in a Swiss Alpine valley. Int J Epidemiol 16(2):282–287
67. Marrie TJ (1990) Q fever–a review. Can Vet J 31(8):555–563
68. Hackstadt T, Williams JC (1981) Biochemical stratagem for obligate parasitism of eukaryotic cells by Coxiella burnetii. Proc Natl Acad Sci USA 78(5):3240–3244
69. Haubitz S, Hitz F, Graedel L et al (2014) Ruling out Legionella in community-acquired pneumonia. Am J Med 127(10):1010–1019
70. File TM (2009) The science of selecting antimicrobials for community-acquired pneumonia (CAP). J Manag Care Pharm 15(2 Suppl):S5–S11
71. Atkinson TP, Balish MF, Waites KB (2008) Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev 32(6):956–973
72. Sakai T, Ishida T, Arita M et al (2015) A study on the clinical course and antimicrobial susceptibility of Mycoplasma pneumoniae in a community hospital. Kansenshogaku Zasshi 89(4):458–464
73. Principi N, Esposito S (2013) Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection. J Antimicrob Chemother 68(3):506–511
74. Blasi F, Tarsia P, Aliberti S (2009) Chlamydophila pneumoniae. Clin Microbiol Infect 15(1):29–35
75. CDC (2010) Case definitions for infectious conditions under public health surveillance. National Notifiable Diseases Surveillance System, CDC
76. Marrie TJ (2004) Q fever pneumonia. Curr Opin Infect Dis 17(2):137–142
77. Jarraud S, Descours G, Ginevra C, Lina G, Etienne J (2013) Identification of legionella in clinical samples. Methods Mol Biol 954:27–56
78. Cloud JL, Carroll KC, Pixton P, Erali M, Hillyard DR (2000) Detection of Legionella species in respiratory specimens using PCR with sequencing confirmation. J Clin Microbiol 38(5):1709–1712
79. Marrero M, Raoult D (1989) Centrifugation-shell vial technique for rapid detection of Mediterranean spotted fever rickettsia in blood culture. Am J Trop Med Hyg 40(2):197–199
80. Shimada T, Noguchi Y, Jackson JL et al (2009) Systematic review and metaanalysis: urinary antigen tests for Legionellosis. Chest 136(6):1576–1585
81. Welti M, Jaton K, Altwegg M, Sahli R, Wenger A, Bille J (2003) Development of a multiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in respiratory tract secretions. Diagn Microbiol Infect Dis 45(2):85–95
82. Stralin K, Backman A, Holmberg H, Fredlund H, Olcen P (2005) Design of a multiplex PCR for Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae and Chlamydophila pneumoniae to be used on sputum samples. APMIS 113(2):99–111
83. Nomanpour B, Ghodousi A, Babaei T, Jafari S, Feizabadi MM (2012) Single tube real time PCR for detection of Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydophila pneumoniae and Legionella pneumophila from clinical samples of CAP. Acta Microbiol Immunol Hung 59(2):171–184
84. Potts A, Donaghy M, Marley M et al (2013) Cluster of Legionnaires disease cases caused by Legionella longbeachae serogroup 1, Scotland, August to September 2013. Euro Surveill 18(50):20656
85. Fenollar F, Raoult D (2004) Molecular genetic methods for the diagnosis of fastidious microorganisms. APMIS 112(11–12):785–807
86. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM (2004) Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 20(4):555–563
87. Garau J, Fritsch A, Arvis P, Read RC (2010) Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp. J Chemother 22(4):264–266
88. Dunbar LM, Farrell DJ (2007) Activity of telithromycin and comparators against isolates of Legionella pneumophila collected from patients with community-acquired respiratory tract infections: PROTEKT years 1–5. Clin Microbiol Infect 13(7):743–746
89. Blazquez Garrido RM, Espinosa Parra FJ, Alemany FL et al (2005) Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis 40(6):800–806
90. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ (2000) Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 31(2):347–382
91. Waites KB, Crabb DM, Duffy LB (2003) Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae. Int J Antimicrob Agents 21(6):574–577
92. Bebear CM, Renaudin H, Bryskier A, Bebear C (2000) Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrob Agents Chemother 44(7):1980–1982
93. Miyashita N, Kawai Y, Inamura N et al (2015) Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults. J Infect Chemother 21(3):153–160
94. Radisic M, Torn A, Gutierrez P, Defranchi HA, Pardo P (2000) Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment. Clin Infect Dis 31(6):1507–1511
95. Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T (2008) Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect 57(3):223–228
96. Sobradillo V, Zalacain R, Capelastegui A, Uresandi F, Corral J (1992) Antibiotic treatment in pneumonia due to Q fever. Thorax 47(4):276–278
97. Teunis PF, Schimmer B, Notermans DW et al (2013) Time-course of antibody responses against Coxiella burnetii following acute Q fever. Epidemiol Infect 141(1):62–73
98. Anderson A, Bijlmer H, Fournier PE et al (2013) Diagnosis and management of Q fever–United States, 2013: recommendations from CDC and the Q Fever Working Group. MMWR Recomm Rep 62(RR-03):1–30
99. Jain S, Self WH, Wunderink RG et al (2015) Community-acquired pneumonia requiring Hospitalization among US adults. N Engl J Med 373(5):415–427
100. Herrera M, Aguilar YA, Rueda ZV, Muskus C, Velez LA (2016) Comparison of serological methods with PCR-based methods for the diagnosis of community-acquired pneumonia caused by atypical bacteria. J Negat Results Biomed 15(1):3
101. Thurman KA, Warner AK, Cowart KC, Benitez AJ, Winchell JM (2011) Detection of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella spp. in clinical specimens using a single-tube multiplex real-time PCR assay. Diagn Microbiol Infect Dis 70(1):1–9
102. Qu J, Gu L, Wu J et al (2013) Accuracy of IgM antibody testing, FQ-PCR and culture in laboratory diagnosis of acute infection by Mycoplasma pneumoniae in adults and adolescents with community-acquired pneumonia. BMC Infect Dis 13:172
103. Mandell LA, Wunderink RG, Anzueto A et al (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 1(44 Suppl 2):S27–S72
104. Murdoch DR, Podmore RG, Anderson TP et al (2013) Impact of routine systematic polymerase chain reaction testing on case finding for Legionnaires’ disease: a pre-post comparison study. Clin Infect Dis 57(9):1275–1281